Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Fundación GECP
Sun Yat-sen University
Weill Medical College of Cornell University
Hoffmann-La Roche